Advertisement Boehringer, WellPoint and HealthCore start new multi-year research collaboration - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Boehringer, WellPoint and HealthCore start new multi-year research collaboration

Boehringer Ingelheim Pharmaceuticals (BIPI), WellPoint and HealthCore are starting a research project to identify gaps in non-valvular atrial fibrillation research, development and treatment.

The project will focus on non-valvular atrial fibrillation (NVAF) and will examine disease prevalence, treatment complications, such as hospital readmissions, as well as the use of evidence-based guidelines.

This is the first project under the parties’ five-year research collaboration deal signed earlier this year.

WellPoint subsidiary HealthCore vice president of research Mark Cziraky said: "This collaborative approach allows us to look at problems collectively.

"It’s this holistic approach to identifying the needs of all stakeholders that will allow us to produce the kind of information used to develop therapies and interventions that provide the most value to members, providers, insurers and medical product developers and manufacturers."

Data secured from the NVAF project is expected to provide the basis for the collaborative development of healthcare interventions, which can be evaluated within WellPoint’s affiliated health plans and provider networks.

The five-year deal will allow the three parties to generate real world evidence as well as develop health economic and outcomes data to inform the development and evaluation of new medicines, guidelines and interventions.